Nizar J Bahlis

44PUBLICATIONS
211CO-AUTHORS
Haematological tumoursNanomedicineMedical bacteriologyMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|Jun 03, 2026
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

|May 05, 2026
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

|Feb 17, 2026
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

C Riedhammer, M Truger, H Lee

|Jan 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Holly Lee, Sungwoo Ahn, Gerone A Gonzales

|Dec 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos

Pageof 8

Frequent Collaborators

8 joint publications

Aurore Perrot

8 joint publications

Saad Z Usmani

7 joint publications

Philippe Moreau

7 joint publications

María-Victoria Mateos